Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects |
Ndolo, Karyn Muzinga
(College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University)
An, Su Jin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University) Park, Kyeong Ryang (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University) Lee, Hyo Jeong (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University) Yoon, Kyoung Bin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University) Kim, Yong-Chul (School of Life Sciences, Gwangju Institute of Science & Technology) Han, Sun-Young (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University) |
1 | Chen, H., Huang, Q., Dong, J., Wang, A. D. and Lan Q. (2008) Overexpression of CDC2/cyclin B1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 8, 29-40. DOI |
2 | Choi, S. J., Moon, M. J., Lee, S. D., Choi, S. U., Han, S. Y. and Kim, Y. C. (2010) Indirubin derivatives as a potent FLT3 inhibitors with antiproliferative activity of acute myeloid leukemic cells. Bioorg. Med. Chem. Lett. 20, 2033-2040. DOI |
3 | Christensen, J. G., Burrows, J. and Salgia, R. (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225, 1-26. DOI |
4 | Ervik, M., Lam, F., Ferlay J., Mery, L., Soerjomataram, I. and Bray, F. (2016) Cancer Today. International Agency for Research on Cancer, Lyon, France. Available from: http://gco.iarc.fr/today/. |
5 | Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., Niederberger, E., Tang, W., Eisenbrand, G. and Meijer, L. (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60-67. DOI |
6 | Kang, Y. K., Muro, K., Ryu, M. H., Yasui, H., Nishina, T., Ryoo, B. Y., Kamiya, Y., Akinaga, S. and Boku, N. (2014) A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest. New Drug 32, 355-361. DOI |
7 | Lee, D. H., Sung, E. S., Ahn, J. H., Huh, J. W. and You, W. K. (2015a) Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther. 4, 35-44. |
8 | Lee, H. J., Lee, J., Jeong, P., Choi, J., Baek, J., Ahn, S. J., Moon, Y., Heo, J. D., Choi, Y. H., Chin, Y. W., Kim, Y. C. and Han, S. Y. (2018) Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia. Oncotarget 9, 924-936. DOI |
9 | Liu, X., Newton, R. C. and Scherle, P. A. (2010) Developing c-Met pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med. 16, 37-45. DOI |
10 | Lemmon, M. A. and Schlessinger, J. (2010) Cell signaling by receptortyrosine kinases. Cell 141, 1117-1134. DOI |
11 | Ma, P. C., Maulik, G., Christensen, J. and Salgia, R. (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast. Rev. 22, 309-325. DOI |
12 | Puri, N., Khramtsov, A., Ahmed, S., Nallasura, V., Hetzel, J. T., Jagadeeswaran, R., Karczman, G. and Salgia, R. (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-3534. DOI |
13 | Moon, M. J., Lee, S. K., Lee, J. W., Song, W. K., Kim, S. W., Kim, J. I., Cho, C. H., Choi, S. J. and Kim, Y. C. (2006) Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem. 14, 237-246. DOI |
14 | Mughal, A., Aslam, H. M., Sheikh, A. and Khan, A. M. H. (2013) c-Met inhibitors. Infect. Agent. Cancer 8, 13. DOI |
15 | Nam, S. K., Scuto, A., Yang, F., Chen, W. Y., Park, S. M., Yoo, H. S., Koning, H., Bhatia, R., Cheng, X., Merz, K. H., Eisenbrand, G. and Jove, R. (2012) Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol. Oncol. 6, 276-283. DOI |
16 | Que, W. and Chen, J. (2011) Knockdown of c-Met inhibits cell proliferation and invasion and increaseds chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol. Med. Rep. 4, 343-349. DOI |
17 | Lee, J. J. X., Chan, J. J. and Choo, S. P. (2015b) Clinical development of c-MET inhibition in hepatocellular carcinoma. Diseases 3, 306-324. DOI |
18 | Smits, V. A. and Medema, R. H. (2001) Checking out the G(2)/M transition. Biochim. Biophys. Acta 1519, 1-12. DOI |
19 | Rodrigues, G. A. and Park, M. (1994) Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 9, 2019-2027. |
20 | Sawyers, C. (2004) Targeted cancer therapy. Nature 432, 294-297. DOI |
21 | You, W. K. and McDonald, D. M. (2008) The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 41, 833-839. DOI |
22 | Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A. and Prior, I. A. (2018) New perspectives, opportunities, and challenges in exploring the human protein kinome. Cancer Res. 78, 15-29. DOI |
23 | Zhu, K., Kong, X., Zhao, D., Liang, Z. and Luo, C. (2014) c-Met kinase inhibitors: a patent review (2011-2013). Expert Opin. Ther. Pat. 24, 217-230. DOI |
24 | Chan, A. O. O. and Wong, B. (2015) Epidemiology of Gastric Cancer (M. F. Post, Ed.). Uptodate. Available from: http://www.uptodate.com/contents/epidemiology-of-gastric-cancer/. |
25 | Annual report of cancer statistics in Korea in 2015 (2017) Korea Central Cancer Registry. Available from: http://www.cancer.go.kr/. |
26 | Blazevic, T., Heiss, E. H., Atanasov, A. G., Breuss, J. M., Dirsch, V. M. and Uhrin, P. (2015) Indirubin and indirubin derivatives for counteracting proliferative disease. Evid. Based Complement. Alternat. Med. 2015, 654098-654110. |
27 | Bradley, C. A., Salto-Tellez, M., Laurent-Puig, P., Bardelli, A., Rolfo, C., Tabernero, J, Khawaja, H. A., Lawler, M., Johnston, P. G. and Van Schaeybroeck, S. (2017) Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat. Rev. Clin. Oncol. 14, 562-576. DOI |